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Abstract
Improvement of identification and education of Hereditary Breast and Ovarian Cancer
Syndrome (HBOC) among primary care providers was the focus of this quality improvement
project. The development of a pre-implementation and post-implementation survey along with
the distribution of a family history screening tool and the Evidence-Based Practice Guidelines
provided by the Centers for Disease Control was introduced for the intervention. The anonymous
surveys were distributed to primary care providers at the University of Miami in Miami-Dade
County locations. Participants recruited for this quality improvement project included Doctors
(MD, DO), Nurse practitioners, and Physician assistants currently practicing in primary care.
The quality improvement project included two surveys using clinical scenarios to assess
primary care providers' knowledge in identifying patients at an increased risk for HBOC. The
providers willing to participate began by taking a pre-implantation survey to assess their baseline
knowledge. The providers then received the Evidence-based Practice Guidelines Supporting
Genetic Susceptibility Testing for Hereditary Breast and Ovarian Cancer Syndrome and the
seven-question family history screening tool. They were then asked to review and implement
these tools into their practice for 6 weeks. After the completion of the 6 weeks, the providers
were then asked to complete a second survey using the provided family history screening tool to
answer clinical scenario questions.
Family history and screening tools were designed to identify at-risk patients for HBOC.
On average, the post-implementation clinical scenario questions while utilizing the family
history screening tool showed an increase in the identification of patients at risk for HBOC in
comparison to the pre-implantation clinical scenario questions where no family history screening
tool was used. While this project cannot make final conclusions due to its sample size, it can
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open opportunities for further validation of this theory and bring further evidence to translate
research into changing clinical practice to better serve the community.

6
Introduction
Hereditary Breast and Ovarian Cancer Syndrome (HBOC) is a genetic condition
associated with an increased risk for breast, ovarian, pancreatic, prostate, and melanoma cancers.
This genetic condition is associated with a gene mutation in the genes BRCA 1 and BRCA 2.
While HBOC only accounts for 5-10% of breast and 15% of ovarian cancer cases, people who
inherit these gene mutations have a greater risk of developing these cancers (Owens et al., 2019).
On average, a woman’s lifetime risk of developing breast cancer and ovarian cancer is 13% and
1.2% (National Cancer Institute, 2014). While patients with a gene mutation in BRCA1 increase
the risk of developing breast cancer to 55-72% and a gene mutation in BRCA2 increase the risk
to 45%-69%. While the risk for ovarian cancer in a gene mutation in BRCA1 is 39%-44% and
BRCA2 is 11%-17% (National Cancer Institute, 2014). These numbers are significant in
comparison to the general population. Patients at an increased risk for HBOC should be
identified and offered increased screening, and prevention strategies. Primary care providers are
the gatekeepers of patients’ health. Their priorities in practice should be to identify patients’ risk
for disease and promote their prevention. The US Preventive Services Task Force (USPSTF)
makes recommendations for disease processes based on evidence and the benefits and harm that
can come from screening patients (Owens et al., 2019). The USPSTF currently recommends that
primary care providers assess their patients for BRCA1/2 with a family risk assessment tool.
Patients with a positive result should be referred for genetic counseling (Owens et al., 2019). The
current family risk assessment tools approved by the USPSTF for screening are the Ontario
Family History Assessment Tool, Manchester Scoring System, Referral Screening Tool,
Pedigree Assessment Tool, Seven-Question Family History Screening, and the International
Breast Cancer Intervention Study Model (Owens et al., 2019). According to the USPTSF, these
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tools are useful predictors in identifying patients with HBOC to be referred for genetic
counseling with a 77%-100% predictor rate (Owens et al., 2019). The issues in question are; do
primary care physicians know how to identify HBOC and what are the knowledge gaps, tools,
and current practices for identifying patients at increased risk for HBOC?

Background
Primary care providers (PCP) are the gatekeepers of their patients’ health. They are the
frontline in identifying patients' risk factors and when it is appropriate to refer patients for further
evaluations. PCPs can aid patient care and prevention of HBOC related cancers by identifying atrisk patients and referring them to genetic counseling for further evaluations. The current issue
when it comes to identifying patients at risk for HBOC is that many primary care providers are
not well versed in the genetic principles that are needed to identify patients with an increased risk
for HBOC (Nair et al., 2017). A systematic review conducted by Hamilton et al. (2016) revealed
that PCPs noted their limitations in their knowledge of genetics and collecting and interpreting
family history data (Hamilton et al., 2016). Hamilton et al. (2016), also revealed one study that
implemented a multicomponent cancer genetics toolkit in order to improve knowledge of PCP
providers in a women’s primary care clinic at a Veterans Administration Medical Center. The
use of this toolkit improved the knowledge of cancer genetics in PCPs from 59% to 73% postimplementation of the toolkit (Hamilton et al., 2016). The more knowledge and confidence PCPs
have with identifying risk factors, or “red flags” associated with HBOC, such as early age of
onset of breast cancer diagnosis (younger than 50 years old), bilateral breast cancer, male breast
cancer, ovarian cancer, multiple affected relatives with the same cancer, Ashkenazi Jewish
decent in their patient or patients’ family history, the more confident they will be in referring
patients for genetic testing and counseling. Genetic testing and counseling for hereditary cancer
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syndrome such as HBOC allow for patients to understand their personal risk for developing
HBOC related cancers. Being referred to genetics for testing and counseling also provides
patients the opportunity to understand their options for screening, prevention, and managing their
risk for HBOC related cancers. It is imperative that PCPs be confident in identifying red flags in
their patients for HBOC related cancer in order for patients to have these important conversations
with the appropriate specialist and increase their surveillance as indicated.

Scope of the Problem
According to the American Cancer Society in the year 2022, 19,880 women will have a
new diagnosis of ovarian cancer, and 12,810 women will die from ovarian cancer (American
Cancer Society, 2022). The 5-year survival rate for ovarian cancer is 49.1% (National Cancer
Institute SEER, 2018a). This poor prognosis is due to the fact that there are difficulties in
detecting ovarian cancer early. For example, ovarian tumors are not palpable on routine exams
unless they are large and by this time it is usually not a good sign. If PCPs could identify patients
with “red flags” and refer them for genetic testing and counseling, then patients could have a
better understanding of their risks and have the necessary conversations of risk, and prevention
strategies. In comparison, breast cancer has a 5-year survival rate of 90.3 % (National Cancer
Institute SEER, 2018b). This is in part due because there is better screening, imaging, and early
detection rates for breast cancer. As noted, in comparing breast cancer survival rates and ovarian
cancer survival rates, we can identify that early detection and screening are crucial to patient
outcomes. One thing to note, in HBOC is a risk for other cancers to develop that fall within this
cancer syndrome such as prostate cancer. A man with a BRCA 1 or BRCA 2 mutation has an
elevated risk with up to an approximately 20% chance of developing prostate cancer (Li et al.,
2013) in comparison with general population who have a risk of 6% (Petrucelli et al., 2016).
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Pancreatic cancer risk is as much as 1-3% with BRCA 1 and between 3-5% for BRCA 2, in
comparison to the general population risk which is 0.5% (Petrucelli et al., 2016). Risk for male
breast cancer in the general population is 0.1%, a man with a BRCA 1 pathogenic variant has a
1-2% risk and BRCA 2 pathogenic variant has a risk of between 6-8% (Petrucelli et al., 2016).
The risk for melanoma is also increased. Though the risk of these other cancers developing is
lower in comparison to breast and ovarian cancer, they are still cancers that are a part and related
to this syndrome and bring individuals at a greater risk for this diseases in comparison to the
general populations risk. Again, PCPs are the gatekeepers and at the frontline of identifying risk
factors for their patients. Helping PCPs to better understand and build confidence in identifying
patient’s female and male who are at increased risk for HBOC could potentially allow their
patients to have better screening and risk management/treatment in relation to the cancers in this
syndrome.

Consequences of the Problem
As previously mentioned, ovarian cancer is the gynecologic cancer with the worst
survival rates and outcomes, due to difficulties in early identification. It has been noted that the
earlier a disease or condition is identified, the better the outcome and survival rate for the patient
is. Unfortunately, women with ovarian cancer or a family history of ovarian cancer are not
receiving genetic testing or counseling and thus missing important information for themselves
and implications for their families. As noted by one study published by Kurian et al., (2019), in
the Journal of Clinical Oncology found that in the timeline between 2013 and 2014 only onequarter of patients with breast cancer and one-third of patients with ovarian cancer had genetic
testing done. 7.8% of patients diagnosed with breast cancer who had genetic testing done were
found to have a pathogenic variant. Conversely, for the patients diagnosed with ovarian cancer
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who had genetic testing done, 14.5% of those patients were found to have a pathogenic variant.
These pathogenic variants that were found warranted change in these patients' care such as a
need for an increase in breast cancer screening, earlier colonoscopy, or risk-reducing surgeries
such as mastectomy, or oophorectomy (Kurian et al., 2019). The consequence of missing patients
with “red flags” for HBOC is the missed opportunity for these high-risk patients to have these
increase in screenings, earlier screenings, or prophylactic risk-reducing surgeries. In addition to
missing one individual at risk, a generation or family could be at risk as these genes can be
passed on from parents and generations before.

Knowledge Gaps
PCPs' knowledge and confidence in referring women with ovarian cancer to genetic
testing and counseling are lacking. As discussed in a cross-sectional study done by Hann et al.
(2017) the authors studied the attitudes of healthcare professionals toward genetic testing and
risk reduction management for ovarian cancer alone. In this study, it was noted that general
practitioners had a large difference in knowledge of ovarian cancer as compared to the other
specialist in this study (Hann et al., 2017). The specialties surveyed in this study included
oncologist, genetics clinicians, general practitioners, gynecologist, and nurses (Hann et al.,
2017). General practitioners scored significantly lower than other disciplines in conducting
cancer risk counseling and knowledge of genetics (Hann et al., 2017). Out of the 10 questions
that were presented in the survey in relation to ovarian cancer and genetics knowledge, general
practitioners median score was 4/10. Versus other subspecialties such as clinical genetics and
oncologist scored in the median ranges of 8/10 and 7/10. These results do not come as a surprise
as general practitioners deal with many health conditions and diseases while the other disciplines
in this study such as genetic clinicians, oncologists, and gynecologists are specialized in the
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disease and genetic process of ovarian cancer. In the study published by the authors Nair et al.
(2017), they sought to see the knowledge of primary care providers as it relates to the
identification of high-risk patients for HBOC. In their study, they noted that there were
knowledge gaps for primary care providers in identifying patients and their families at risk for
HBOC (Nair et al., 2017). They further concluded that PCPs are a critical part of identifying
patients at risk for HBOC and ensuring referral for genetic testing and counseling (Nair et al.,
2017). PCPs should have basic understanding of HBOC and genetics. The understanding and
importance of a patient’s family history, and risk factors that account for their patient’s risk of
HBOC. The goal in identifying patients at risk is to give patients the option of appropriate
consultation with experts in order to have the conversations needed to assess what risk-reducing
screening and or procedure is appropriate for them. The goal of screening and identification of
high-risk patients is prevention.
Literature Search
The literature search identified a total of 109 articles, 6 articles were identified from
CINHAL database, 53 were identified from the PubMed database, and 50 articles were identified
from the Embase database. A total of 1 article was removed before screening due to duplication
giving a total of 108 articles screened. A combination of the words used for this search was
hereditary breast and ovarian cancer syndrome, primary care or primary healthcare, or primary
health care. A total of 32 records were excluded for being older than 10 years, 20 records were
excluded due to publication type. Inclusion criteria for publication type included clinical trials,
meta-analysis, randomized controlled trials, systematic reviews. All other articles were excluded.
A total of 21 articles were excluded due to being the wrong population/disease type. Inclusion
criteria by disease included hereditary breast and ovarian cancer syndrome, breast cancer, or

12
ovarian cancer. All other diseases or cancer syndromes were excluded such as Lynch syndrome,
Li-Fraumeni, Cowden, Peutz-Jeghers, etc. to keep the focus of this literature review on HBOC
and BRCA1/2. 32 articles were screened and excluded by their title or abstract due to being
either the wrong intervention or population such as articles that reviewed preimplantation testing
and experience of risk-reducing surgeries after identification of BRCA mutations. After the
application of inclusion, exclusion, and screening of title and abstracts of articles, 3 articles were
chosen in this method to include in the literature review. 3 articles were identified through other
methods such as citation searching within articles and assessed and included in reviews, giving a
total of 7 studies in this literature review. Figure 1 shows the PRISMA flow diagram process
used to identify, screen, and include studies for this literature review.

Figure 1. PRISMA flow diagram (Page et al., 2020).
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Summary of the Literature

Within the scope of this literature review, it can be noted that genetics is a subspecialty
that most providers during their training do not have the opportunity to fully learn and properly
incorporate into their practice. As noted in the literature, providers with a greater time in practice
had more knowledge and experience with HBOC than those with less experience. These
knowledge gaps can be closed by providers in their continued effort to seek continuing education
and incorporate the use of guidelines such as those recommended by the USPSTF. These
guidelines can potentially allow for providers to screen and identify patients at high risk for
HBOC. The first step in closing this gap though is educating primary care providers on HBOC,
the importance of a detailed personal and family history intake, and the interpretation of the
family history in order to accurately use guidelines to help identify patients at risk for HBOC.
The studies included in this review revealed that there are not many studies that analyzed large
cohorts of participants, thus potentially skewing, and not accurately portraying general results.
Though these studies were of small cohorts across the U.S similar patterns and results were
revealed in each study. Future studies should also focus on whether providers have heard of these
guidelines and based on the guidelines if they are able to correctly screen and identify these highrisk patients (Bellcross et al., 2011). There are still gaps and concepts to be understood in this
topic, but a consensus can be made that there is a potential knowledge deficit in the primary care
setting with regard to HBOC, and patients at high risk are not being identified, thus causing
potential harm to patients and their families who should be receiving increased screening or
further evaluation.
Literature Review
Knowledge Deficit in Primary Care
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One of the themes revealed in the literature review is that of a knowledge deficit in
primary care providers in identifying patients at an increased risk for HBOC. The study
published in the Journal of Cancer Education by authors Nair et al. (2017), aimed to assess and
evaluate Georgia primary care providers' knowledge of HBOC (Nair et al., 2017). This study was
able to do so in providing surveys to primary care providers across Georgia. The survey
questions assessed primary care providers knowledge of HBOC, BRCA gene mutation
inheritance pattern, referral pattern to genetics in their practice, and clinical scenarios for the
primary care providers to identify what family history pattern or patient is at the highest risk for
HBOC (Nair et al., 2017). Consequently, 44% of providers reported referring patients to genetic
counseling but 92.1% failed to recognize ovarian cancer at any age as a risk factor for HBOC
(Nair et al., 2017). Of the two basic knowledge questions asked with regard to inheritance
patterns and first-degree relative risk 53.4 and 39% of primary care providers correctly answered
these questions (Nair et al., 2017). For the last two questions that assessed clinical application for
high-risk patients there was a 37.1% and a 3.9% correct response rate (Nair et al., 2017). The
limitations identified were that this study was limited to only providers in the state of Georgia.
These results do not reflect the knowledge and consensus of all primary care providers in
Georgia, let alone across the country. Another limitation noted was the study sampling size.
Again, this cohort of participants in this study only represents less than 1% of all primary care
providers in the state of Georgia (Nair et al., 2017). Though this study has limitations, it did
provide many details and insight into the knowledge of primary care providers and HBOC. This
study helped to suggest that primary care providers are not properly recognizing patients at risk
for HBOC and that screening tools implemented into the primary care setting can help to
improve the identification of patients at high risk. Correspondingly, a more recent study
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published in the Journal of Genetic Counseling by authors Dekanek et al. (2019) also conducted
a study of primary care providers' knowledge and confidence in regard to HBOC. In this study, a
questionnaire was designed to assess the knowledge of primary care providers about BRCA1/2,
including inheritance patterns, indications for testing, and confidence in communicating result
interpretations (Dekanek et al., 2019). The surveys revealed that among the primary care
providers, there were several gaps identified for BRCA1/2 knowledge (Dekanek et al., 2019).
The average score to correct answers to knowledge questions for BRCA1/2 was 73%. In the
surveys conducted, they also revealed that participants were not confident in their abilities to
counsel or test patients for BRCA1/2 about 50% of participants revealed that they felt confident
in counseling or discussing testing with patients about BRCA1/2. (Dekanek et al., 2019).
Limitations to this study included that the participants in this study were from a large academic
hospital with more than half of the participants having 15 years or more experience as clinicians.
The study population is not representative of all primary care providers as many do not work in
large academic hospitals with resources to geneticists or genetic counselors (Dekanek et al.,
2019). With that being mentioned, it still conveys the need for more education of primary care
providers, and the possibility of incorporation of tools to aid clinicians in any setting. In
comparison, the study published by authors Trivers et al. (2011) also conducted a vignette survey
study amongst primary care providers across the United States that sought to investigate primary
care providers adherence to referring patients to genetic counseling based on their risk for
ovarian and breast cancer (Trivers et al., 2011). In this vignette study, 41% of primary care
providers failed to identify patients at high risk for ovarian and breast cancer, while 74%
mislabeled average risk patients as high-risk patients while only 65% of clinicians were able to
correctly identify patients as high risk for breast or ovarian cancer (Trivers et al., 2011). These
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numbers are concerning because real patients could be missed or looked over because the
healthcare provider cannot properly identify patients at an increased risk. This study had its
limitations in that it was a vignette-based study it does not necessarily reflect a health care
provider's practice (Trivers et al., 2011). It is also uncertain of the guidelines these health care
providers were following when analyzing the vignette-based surveys. For example, the USPSTF
recommends the use of family history screening tools such as the ones mentioned earlier in this
review. Another study published in the American Journal of Preventative Medicine by authors
Bellcross et al. (2011) also analyzed the knowledge and awareness of BRCA amongst primary
care providers in the U.S. (Bellcross et al., 2011). This study included 4 scenarios for primary
care providers to identify whether it was considered an increased risk, or low risk for HBOC
based on family history pattern in relation to the USPSTF guidelines. The participants were also
asked if they were aware of the BRCA testing and if they had ever ordered BRCA testing for
their patients. Of the 1,500 primary care providers who participated, 87% were aware of the
BRCA testing and 25% reported to have ordered BRCA testing in the last year, (Bellcross et al.,
2011). It was noted in this study that providers who were aware of testing and had ordered
BRCA testing were more likely to recognize a high-risk scenario than the providers who
answered that they were aware of testing but had never ordered BRCA testing (Bellcross et al.,
2011). This study suggests that many providers do not recognize patients at risk for HBOC
through family history as suggested by the USPSTF guidelines (Bellcross et al., 2011). This
study had its limitations in that it does not fully represent all primary care provider's practices in
the U.S., and it did not seek to ask if providers were aware of the USPSTF guidelines and
recommendations for patients at risk for HBOC. Amongst the literature, it can be noted that there
is a knowledge gap amongst primary care providers and identifying patients at an increased risk
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for HBOC. Guidelines that are set in place such as those recommended by the USPSTF allow for
providers to properly screen and identify at-risk patients.

Prevalence of Referral
For patients to be referred to genetics for counseling, they must first be identified by their
primary care providers. The following study conducted by authors Quillin et al. (2014), sought to
analyze the prevalence of referrals to genetic counseling for patients at risk for HBOC. The
participants in this study were asked to complete a survey that included questions about their
personal and family history of breast and ovarian cancer. The participants were then categorized
as high risk by the USPSTF guidelines for BRCA referral for counseling and testing and then
asked if they had ever met with a genetic counselor or had been referred for testing (Quillin et
al., 2014). Of the 486 participants, 22 participants met the criteria for BRCA counseling and
testing with only one participant stating they met with a genetic counselor. However, this
participant did not undergo genetic testing (Quillin et al., 2014). The results from this study
suggested that 1:22 patients in a primary care setting qualify for referral to genetics-based on
current guidelines (Quillin et al., 2014). The limitations in this study included that family history
was self-reported and not verified. This study was also only conducted in a single institution and
does not reflect the general population. Family history is an important implication for identifying
patients based on USPSTF guidelines. Primary care providers are at the forefront of proper and
detailed patient family histories in order to identify at-risk patients when using guidelines such as
those recommended by the USPSTF. In an earlier study conducted by Bellcross et al. (2013) they
also assessed the prevalence of patients meeting USPSTF guidelines for increased risk of HBOC
and whether these patients were referred to genetics for counseling or testing. In this study, the
participants' family history was collected and assessed for increased risk as determined by
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USPSTF guidelines. They were divided into groups of patients with a personal history of cancer,
and no personal history of cancer. Roughly 90% of participants in this study who met USPSTF
guidelines for referral had a conversation with their primary care providers about their family
history. It was revealed in this study though, that only 20% of the participants had been referred
to genetics for counseling (Bellcross et al., 2013). Mirroring similar results as the study
conducted by Quillin et al. (2014). In the literature, it is noted that though patients are having
conversations with their primary care providers about their family history, patients at high risk
for HBOC are not being identified and referred to genetics for counseling.
PICO Clinical Question
P- In patients at risk for hereditary breast and ovarian cancer syndrome (HBOC)

I- Does the use of an evidence-based family history screening tool in the primary care setting

C- N/A

O- Increase the identification of patients at risk for hereditary breast and ovarian cancer
syndrome?
Primary DNP Project Goal
The primary goal of this quality improvement project is to understand the effects of
implementing an evidenced-based family history screening tool in the primary care setting in
order to increase the identification of patients at risk for hereditary breast and ovarian cancer
syndrome. By achieving this project goal, the knowledge and confidence of primary care
providers in identifying patients at risk for hereditary breast and ovarian cancer syndrome
(HBOC) can be further understood. Implementing an evidence-based family history screening
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tool into the primary care setting can further provide primary care providers with the appropriate
tools needed to identify and increase the identification rate of patients at risk for HBOC.
Identification of these patients at risk for HBOC and referral to genetic care can potentially
detect genetic mutations in these patients that have preventative screening and guidelines.
Currently, at the University of Miami where the quality improvement project is taking place,
there is no policy in place in relation to hereditary breast and ovarian cancer syndrome screening.
For example, the University of Miami has a policy in place that provides guidelines for referral
to the Lung Cancer Screening Program, screening criteria, screening procedures, and pulmonary
nodule management through the recommendation for lung cancer screening according to the
USPSTF and National Comprehensive Cancer Network (NCCN) guidelines. No policy or
procedures exist at the University of Miami for hereditary breast and ovarian cancer syndrome.
In the University of Miami’s electronic health record that is utilized, family history intake and a
pedigree can be taken and created, but once the information is put into the electronic health
record, there is no alert or clinical decision support functionality. The provider is left to interrupt
the data and information that has been collected on the patient.
As noted in the literature, primary care providers lack the knowledge and confidence in
identifying patients at an increased risk for HBOC. As revealed in the study conducted by Nair et
al. (2017) Primary care providers have limited knowledge of HBOC. Including knowledge
deficits in inheritance patterns, and failure to recognize the significance of personal and family
history as it relates to HBOC. This study suggested that patients at risk for HBOC may not be
regularly identified (Nair et al., 2017). As also published by Childers et al. (2017), revealed the
national estimates of genetic testing in women with a history of breast or ovarian cancer noted
that less than one in five individuals with a history of breast cancer or ovarian cancer met the
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criteria for genetic testing under NCCN guidelines underwent genetic testing (Childers et al.,
2017). In identifying these knowledge deficits and lack of referral to genetics in the primary care
setting through the literature, as well as no current policy or procedure in the immersion site, this
project aims to increase provider awareness, confidence and increase the identification of
patients at risk for HBOC through the use of evidence-based guidelines screening tools

Objectives
“SMART” is an acronym that stands for specific, measurable, attainable, realistic, and
timely objectives. This acronym is used to identify the objectives and activities needed to
accomplish the goals of a project (Centers for Disease Control and Prevention, 2021c). The
SMART Goal Form provided by the Centers for Disease Control and Prevention will be used to
understand the process of developing SMART goals. The SMART goals for this quality
improvement project are shown in Table 1.
Table 1.
Not-so-SMART objective: Increase the knowledge and identification rate of patients at
risk for hereditary breast and ovarian cancer syndrome in the primary care setting.
Key Component
Objective
Specific - What is the specific
To increase the knowledge and provide primary
task?
health care providers with educational materials and
an evidence-based family history screening tool to
use in practice in order to help providers easily
identify patients at risk for HBOC.
Measurable - What are the
Surveys/questionnaires will be provided to primary
standards or parameters?
care providers after approval by the Internal Review
Board (IRB) of UM and FIU. Data will be collected
and interpreted using REDcap.
Achievable - Is the task feasible? The project is feasible secondary to the availability
of primary care providers willing to participate in
this project.
Realistic - Are sufficient
The University of Miami is a research and teaching
resources available?
facility, and the recruitment of primary care
providers will facilitate data collection. This project
will provide insight into patient screening and
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Time-Bound - What are the start
and end dates?

promote the increase of knowledge and
identification of patients at an increased risk for
HBOC.
The project will be implemented and completed
between July of 2022 and October of 2022.

SMART objective 1: From July of 2022 through October of 2022, implementation, and
the use of educational and evidence-based family history screening tools into primary
care providers practice will be used with the initiative of increasing the knowledge of
providers and identification of patients at risk for HBOC.
(Centers for Disease Control and Prevention, 2021c).
Definition of Terms
Hereditary breast and ovarian cancer syndrome (HBOC): is a genetic conditions that
increases the likely hood of a person to develop breast, ovarian and other forms of cancer
(Centers for Disease Control and Prevention, 2021a).
Hereditary: received or capable of passing from an ancestor to an offspring (Merriam-Webster
Dictionary, 2019).
Gene mutation: a variation or change in the DNA sequence of a gene.
Pathogenic variant: a gene mutation known to cause and increase the likely hood of disease.
Genetic counseling: the processes of assisting affected or at-risk individuals in understanding
their disease risk and risk management options (National Cancer Institute, 2012).
Genetic counselor: healthcare professional with a graduate education and training in genetics.
Conceptual Underpinning and Theoretical Framework
The Donabedian model will be utilized as the conceptual underpinning for this quality
improvement project. The Donabedian model is the standard approach for assessing quality in
healthcare. The model includes three categories: structure, process, and outcome (Howell &
Stevens, 2020). The structure includes evaluating the characteristics of the healthcare system.
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The process encompasses the specific and measurable actions that are theorized to have an
impact on the outcome measures, and the outcome includes the goal or the impact on patient care
(Howell & Stevens, 2020). In using this model, the structure of the healthcare system creates the
process of care, in this scenario the primary care providers in this institution do not have a policy
or procedure to identify patients at high risk for HBOC (Howell & Stevens, 2020). No family
history screening tools or policies and procedures to identify patients at risk for HBOC results in
patients at increased risk are being missed and there is a missed opportunity for increased
screening or measures for patients to take in preventing their cancer risk (Howell & Stevens,
2020). The purpose of this quality improvement project and in using this model is to increase
primary care providers' knowledge and provide healthcare providers with the necessary
evidence-based screening tools to identify and refer patients at risk for HBOC. Lewin’s Change
theory will be utilized as the theoretic framework to guide this quality improvement project.
Lewin’s Change Theory is a three-step model with the proposition that behavior is a dynamic
balance of forces working in opposition (Gorbunoff et al., 2014). These driving forces encourage
change by driving participants in the desired direction and inhibiting forces that could impede
change (Gorbunoff et al., 2014). In this three-step model theory, the first step of altering
behavior and “unfreezing” begins with analyzing the current organization and its current
practices. In doing so, the primary care providers of the organization can become aware of
current practice guidelines, education, and tools that are available to aid in the practice and
identify patients at an increased risk for HBOC as compared to their current practice. The second
step involves the change and so-called “movement” needed to achieve the change in current
practice. This will include providing primary care providers with the necessary educational
handouts and family history screening tools needed to be successful in identifying patients at
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increased risk for HBOC. These educative hand out’s and family history screening tools will
allow for providers to understand the reasoning and rationale of which patients are at an
increased risk and help to identify patients at an increased risk. Lastly, the third step in the theory
involves “refreezing,” which includes reinforcing this new change in practice. Reinforcing the
importance of identification of patients at increased risk for HBOC by using evidence-based
guidelines will help to change the cultural norm of the organization. The proposed quality
improvement project “The Effect of Implementing an Evidence-Based Family History Screening
Tool in the Primary Care Setting to Increase the Identification of Patients at Risk for Hereditary
Breast and Ovarian Cancer Syndrome” will address the current clinical practice and create a
cultural norm and improve the clinical practice of primary care providers in using evidencebased guidelines to identify patients at an increased risk for HBOC.
Methodology
Setting, Participants and Description of Approach and Project Procedures

This project was conducted through the use of surveys. Potential participants were
identified from the healthcare provider staff lists at the University of Miami Primary Care
Provider website. This staff list is public information and gives the name of each health care
provider that works at each site. The health care providers emails are listed on the University of
Miami people directory website which is also public information. Potential participants were
invited to participate in the quality improvement project by email. Physicians (MD/DO) who
specialize in internal medicine, family medicine, currently practicing in a primary care setting,
Nurse Practitioners currently practicing in a primary care setting, Physician Assistants currently
practicing in a primary care setting at the University of Miami sites were identified and asked to
participate via email. The questionnaires were conducted via a digital survey using REDcap.
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REDcap web application is a secure web application used for building and managing
online surveys and databases. The initial survey includes clinical scenario questions to assess the
healthcare providers knowledge in identifying patients at risk for HBOC according to USPSTF
guideline family history screening tool “Seven-Question Family History Screening (U.S
Preventative Services Task Force, 2019).” The initial questionnaire is presented in table 3. Once
the knowledge assessment was completed by the provider, they received a copy of the
“Evidence-based practice guidelines supporting genetic susceptibility testing for hereditary
breast and ovarian cancer syndrome tool (Centers for Disease Control and Prevention, 2021b).”
This tool can be found and is provided by the Centers for Disease Control and Prevention and is
intended to assist primary care providers with the information and evidence-based guidelines set
forth by USPSTF recommendations. The full supplemental tool can be found in appendix B. The
primary care providers participating in this quality improvement project were also provided with
a copy of the Seven-Question Family History Screening tool to implement into their daily
practice. This tool is provided in table 4. The goal of this project was to provide primary care
providers with the tools and guidelines needed to identify patients at risk for HBOC. The
providers had 6 weeks to review and incorporated the tools into their practice. After the 6 weeks,
the providers were asked to complete a second digital REDcap survey assessing their knowledge
and confidence in identifying increased risk for HBOC via clinical scenarios. The postassessment questionnaire is presented in table 5. This quality improvement project was
dependent on primary care provider's willingness to participate. It was also dependent on the
provider's willingness to read and update their knowledge on the current guidelines that were
provided. It is important for providers to understand the importance of family history screening
as it relates to their patient's health history and indication for screening or referrals.
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SWOT Analysis
A SWOT analysis is a method that can be used to evaluate the strength, weaknesses,
opportunities, and threats that can have an effect on achieving the project goal (Centers for
Disease Control and Prevention, 2021d). The University of Miami is a large teaching and
research hospital, which gives to its providers and patient population an opportunity to learn and
experience new research and advances in medicine. Strengths to take into consideration for this
quality improvement project also include the many disciplinaries and specialties that are within
the health care system. Allowing for any provider in this system to have access to specialists and
referrals for their patients. It can be noted that at the start of a new quality improvement project
there will be a need to recruit and retain participants for said project. This attrition can be seen as
a threat and weakness that can affect the quality improvement project. Other weaknesses and
threats identified for the project included acceptance of changes in providers' practices. The full
SWOT analysis is provided in Table 2.
Table 2. SWOT Analysis
Internal Factors
Strengths




Weaknesses

Research and teaching hospital
Many disciplinary and specialties at
hand for primary care providers and
outreach for support
Experienced staff





No current policy or procedure in
place for identification of HBOC
Recruitment of primary care providers
to participate in project
Retention of primary care providers to
continue with project

External Factors
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Opportunities



Participants of the project are all
within the University of Miami health
care system
Incentive for primary care providers to
increase their knowledge on HBOC

Threats




Acceptance of change and
implementation of screening tool to
practice
Increase in time it takes to collect and
analyze family history
Continuation and maintenance of the
project after it has been implemented

Protection Of Human Subjects
The proposed quality improvement project qualified as exempt research according to the
U.S Department of Health and Human Services Office for Human Research Protections pursuant
to 45 CFR 46.104:

(i) The information obtained is recorded by the investigator in such a manner
that the identity of the human subjects cannot readily be ascertained, directly
or through identifiers linked to the subjects;
(ii) Any disclosure of the human subjects' responses outside the research
would not reasonably place the subjects at risk of criminal or civil liability or
be damaging to the subjects' financial standing, employability, educational
advancement, or reputation; or
(iii) The information obtained is recorded by the investigator in such a manner
that the identity of the human subjects can readily be ascertained, directly or
through identifiers linked to the subjects, and an IRB conducts a limited IRB
review to make the determination required by §46.111(a)(7).
Participants for this quality improvement project were recruited through email; potential
participants were those who are currently specialized in family medicine or internal medicine,
practicing primary care. Including Nurse Practitioners, Physician Assistants, Doctor of Medicine
(MD), or Doctors of Osteopathic Medicine (DO). The information and data obtained during this
project was in a manner that did not identify the participants.
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Participants responses were not linked to their identity. (No identifying information was included
on the surveys and the documents were not coded and linked to the individual’s identity.) The
researchers were able to track who had responded to the surveys via a participant list that
contains email addresses, but the researchers did not know which individual survey belonged to
which respondent/participant. All surveys completed by participants did not ask for participants
name or identifying information. All electronic data was maintained on an encrypted device
requiring a password for access. Surveys were completed through the University of Miami
REDCap web portal program, which is password protected and only the student researcher
involved in the study had access to the study survey within the REDCap system. The topic
addressed would not reasonably place the subjects at risk of criminal or civil liability or be
damaging to the subjects' financial standing, employability, educational advancement, or
reputation.

The consent process was initiated with study participants prior to starting any research
procedures. Participants were given ample time to consider their agreement. Consent was
obtained voluntarily prior to initiating any study procedures: Potential participants were asked to
complete consent and acknowledgment of participation in the research project through electronic
consent using the University of Miami REDcap web platform. Consent was provided to reassure
potential participants that their participation is voluntary, no personal information will be asked
or disclosed, and there are no negative consequences to not taking place in the project,
participating in the project involves no risk. Benefits to participating in the quality improvement
project include primary care providers increasing their knowledge of HBOC and the use of
screening tools to identify patients at risk for HBOC. While others involved may benefit from the
knowledge obtained from this research quality improvement project.
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This study was approved by the IRB at The University of Miami, Miami, FL and Florida
International University, Miami, Florida.

Data Collection
The collection of data was acquired from the Pre-Implementation Primary Care Provider
Assessment and from the Post-Implementation Primary Care Provider Assessment surveys.
These surveys were anonymous and completed through the University of Miami’s REDcap
survey application. A web link was sent to agreeing participants via email for access to both
surveys. Once completed, the providers were provided with the Seven-Question Family History
Screening Tool which can be found in table 4 and the Evidence-based Practice Guidelines
Supporting Genetic Susceptibility Testing for Hereditary Breast and Ovarian Cancer Syndrome
guideline, which can be found in Appendix B. Participants' knowledge and confidence in HBOC,
and identification of at-risk patients were assessed. This was achieved by utilizing clinical
scenario questions that included assessing knowledge of inheritance patterns, and current clinical
practice. After the providers reviewed and utilized the family history screening tool in their
practice for 6 weeks, they were then asked to complete a second and final post-implementation
primary care provider's assessment survey. The post-implementation survey assessed the
provider's knowledge and confidence in identifying patients at an increased risk for HBOC after
reviewing and utilizing the family history screening tool and guideline. Knowledge and
confidence were once again assessed through utilizing patient scenarios, self-reporting of
confidence, and the self-reported numbers of patients that were identified as the increased risk
through the use of the screening tool. The pre- and post-implementation surveys can be found in
Tables 3 and 5.
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Table 3. Pre-implementation Primary Care Provider Assessment
Clinical Scenario
USPSTF Recommendations/ Rationale for
question
As a primary care provide which title would
Assessing how many participants fall in what
best describe you?
healthcare provider category
MD
DO
PA
NP

How many years have you been practicing in
Primary care?

This question will assess how many years of
experience the participant has in practicing in
a primary care setting.

1-3 years
3-6years
6-9 years
10+ years

How confident do you feel in identifying
patients at risk for HBOC?

Assessing providers self confidence in
identifying patients at risk for HBOC.

Very confident
Somewhat confident
Not at all confident

On average how many patients do you
identify at risk for HBOC and refer to
genetics for counseling per month?

Assessing how often providers are identifying
and referring patients to genetics for
counseling.

0-3
5-10
10-20
Do you currently use a screening tool to
assess patients at an increased risk for
HBOC?

Assessing if provider currently uses any
screening tool or guide in practice to identify
HBOC.

Yes
No
A patient can inherit a BRCA 1 or BRCA 2
pathogenic variant from:

Assessing Providers knowledge of inheritance
patterns.
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Their mother only
*Either parent
Their Father only
Which of the following patient scenarios is at
an increased risk for HBOC?
Patient with a family history of their mother
diagnosed with cervical cancer at the age of
50.
Patient with a family history of their father
diagnosed with lung cancer at the age of 70.

In utilizing the Seven-Question Family
History screening tool: Any patient with a
family history of a women with a breast
cancer diagnosis before the age of 50 should
initiate a referral for genetic counseling.

*Patient with a family history of a maternal
aunt diagnosed with breast cancer at the age
of 45.

Which of the following patient scenarios is at
an increased risk for HBOC?

In utilizing the Seven-Question Family
History screening tool: Any patient with a
family history of 2 or more relatives with a
*Patient with a family history of their paternal diagnosis of breast cancer should initiate
grandmother diagnosed with breast cancer at
referral for genetic counseling.
the age of 60 and their paternal aunt
diagnosed with breast cancer at the age of 65.
Patient with a family history of their father
diagnosed with basal cell carcinoma at the age
65 and their mother diagnosed with basal cell
carcinoma at the age 60.
Patient with a family history of a maternal
cousin who was diagnosed with cervical
cancer diagnosed at the age of 50.
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Which of the following patient scenarios is at
an increased risk for HBOC?
Patient with a family history of their mother
diagnosed with cervical cancer at the age of
50

In utilizing the Seven-Question Family
History screening tool: Any first degree
relative with a history of breast cancer should
initiate referral for genetic counseling.

*Patient with a family history of their sister
diagnosed with breast cancer at the age of 60
Patient with a family history of their father
diagnosed with lung cancer at the age of 70
Which of the following patient scenarios is at
an increased risk for HBOC?
*Patient with a family history of a paternal
grandmother diagnosed with bilateral breast
cancer at the age of 60

In utilizing the Seven-Question Family
History screening tool: any relative with a
diagnosis of bilateral breast cancer should
initiate a referral for genetic counseling.

Patient with a family history of a maternal
cousin diagnosed with breast cancer at the age
of 70
Patient with a family history of a paternal
aunt diagnosed with cervical cancer at the age
of 50.
*Indicates correct answer

Table 4. Post-implementation Primary Care Provider Assessment
Questions
Rationale
Was the screening tool helpful in your
Assessing providers opinion on helpfulness of
everyday practice in identifying patients at an using screening tool in practice.
increased risk for HBOC?
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Very helpful
Somewhat helpful
Not at all helpful
How confident are you in identifying patients Assessing primary care providers confidence
at an increased risk for HBOC while using the in identifying patients at increased risk for
screening tool?
HBOC post implementation of screening tool.
Very confident
Somewhat confident
Not at all confident
On average how many patients were
identified at increased risk for HBOC after
implementation of the screening tool?

Assessing how often providers are identifying
and referring patients to genetics for
counseling after implementation of screening
tool.

0-3
5-10
10-20
A patient can inherit a BRCA 1 or BRCA 2
pathogenic variant from:

Assessing Providers knowledge of inheritance
patterns.

Their mother only
*Either parent
Their Father only
In using the screening tool: Which of the
following patient scenarios is at an increased
risk for HBOC?
Patient with a family history of their mother
diagnosed with cervical cancer at the age of
50.
Patient with a family history of their father
diagnosed with lung cancer at the age of 70.
*Patient with a family history of a maternal
aunt diagnosed with breast cancer at the age
of 45.

Assessing the usability in identifying patients
at risk for HBOC with family history
screening tool. Will compare Preimplementation answers VS Postimplementation answers.
In utilizing the Seven-Question Family
History screening tool: Any patient with a
family history of a women with a breast
cancer diagnosis before the age of 50 should
initiate a referral for genetic counseling.
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In using the screening tool: Which of the
following patient scenarios is at an increased
risk for HBOC?
Patient with a family history of their mother
diagnosed with cervical cancer at the age of
50
*Patient with a family history of their sister
diagnosed with breast cancer at the age of 60

Assessing the usability in identifying patients
at risk for HBOC with family history
screening tool. Will compare Preimplementation answers VS Postimplementation answers.
In utilizing the Seven-Question Family
History screening tool: Any first degree
relative with a history of breast cancer should
initiate referral for genetic counseling.

Patient with a family history of their father
diagnosed with lung cancer at the age of 70

.

In using the screening tool: Which of the
following patient scenarios is at an increased
risk for HBOC?

Assessing the usability in identifying patients
at risk for HBOC with family history
screening tool. Will compare Preimplementation answers VS Post*Patient with a family history of their paternal implementation answers.
grandmother diagnosed with breast cancer at
the age of 60 and their paternal aunt
diagnosed with breast cancer at the age of 65. In utilizing the Seven-Question Family
History screening tool: Any patient with a
Patient with a family history of their father
family history of 2 or more relatives with a
diagnosed with basal cell carcinoma at the age diagnosis of breast cancer should initiate
65 and their mother diagnosed with basal cell referral for genetic counseling.
carcinoma at the age 60.
Patient with a family history of a maternal
cousin who was diagnosed with cervical
cancer diagnosed at the age of 50.

In using the screening tool: Which of the
following patient scenarios is at an increased
risk for HBOC?

Assessing the usability in identifying patients
at risk for HBOC with family history
screening tool. Will compare Preimplementation answers VS Postimplementation answers.
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*Patient with a family history of a paternal
grandmother diagnosed with bilateral breast
cancer at the age of 60

In utilizing the Seven-Question Family
History screening tool: any relative with a
diagnosis of bilateral breast cancer should
initiate a referral for genetic counseling.

Patient with a family history of a maternal
cousin diagnosed with breast cancer at the age
of 70
Patient with a family history of a paternal
aunt diagnosed with cervical cancer at the age
of 50.
*Indicates correct answer

Educational Resources/ Family History Screening Tool
Table 5. Seven-Question Family History Screening Tool
No. Questions
1
Did any of your first-degree relatives have breast or ovarian cancer?
2
Did any of your relatives have bilateral breast cancer?
3
Did any man in your family have breast cancer?
4
Did any woman in your family have breast and ovarian cancer?
5
Did any woman in your family have breast cancer before age 50 y?
6
Do you have 2 or more relatives with breast and/or ovarian cancer?
7
Do you have 2 or more relatives with breast and/or bowel cancer?
*One positive response initiates referral (U.S Preventative Services Task Force, 2019)

Data Management
The collection of consents was done electronically through REDcap. The collection of
survey data was also done through REDcap, which is a secure web platform for building and
managing online databases and surveys. Data collection and consents were stored through this
platform and is password protected. Only researchers invited to participate in this project on
REDcap were able to access or view the data. The information in this web platform will not be
linked to the participant's identity secondary to the implementation of anonymous surveys. No
personal information was asked of the participants during the surveys and of individuals who did
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not agree to participate in this project. Data analysis was performed by the quality improvement
team members after the completion of data collection through the ability to export data from
Redcap into a CSV file.
Discussion
Limitations
The delayed launch of this quality improvement project was impacted by the Internal
Review Boards at the University, and at the clinical site. Despite submitting protocols early, the
quality improvement project approval was given by the University in July 2022, while the
clinical site approval was received in August 2022.
The project length and implementation of the project was originally proposed to begin in
June 2022 and to be implemented for 12 weeks. The project was reduced to 6 weeks due to this
delay in approval. Thus, our time for recruitment was also reduced. Despite reaching out to those
identified as potential participants for participation (n=41) the response rate to the initial survey
was low (n=5) bringing the total response rate to 12.2%. While post-implementation response
rate was decreased (n=3) as participants were lost to attrition. Though the sample size is
considered small for research standards, this project can reveal the potential knowledge gaps and
bring interest to bigger studies on this topic. As this quality improvement project has taken place
in only one institution, the results of this project would not reflect the standard of practice for all
primary care providers or for the providers within this institution. More research on the topic of
the knowledge deficit of primary care providers in relation to HBOC is needed, but this project
can open the discussion and further add to the literature.

Results
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As noted from previous studies, the literature has demonstrated that primary care
providers have shown to have a knowledge deficit when it comes to HBOC. The literature has
also demonstrated that in primary care providers not being able to identify at-risk patients for
HBOC there is a decrease in referral rates to genetics for appropriate counseling.
A paired sample t-test was performed to determine the statistical significance. Participants
average scores were compared pre-implementation and post-implementation of the use of a family
history screening tool. On average, pre-implementation clinical questions scores were worse
(M=75, SD= 43.30) than compared to post-implementation where the use of the family history
screening tool implementation was used (M=86.66, SD= 23.09). This improvement though of
11.66, was not statistically significant, t(2)= 3.46, p =.762. Though at this time there is no statistical
significance, an inference can be made that if a larger population was used the hypothesis can be
accepted as it was noted that average scores pre-implementation and post-implementation
improved.
Results from the pre-implementation survey revealed that 40% of participants identified
themselves as MD, 40% of providers identified themselves as NP and 20% of providers
identified themselves as DO. On average, 60% of providers identified as having 10+ of year's
experience, 20% had 6-9 years of work experience, and 20 percent of providers had 3-6 years of
experience. 40% of providers rated themselves as very confident in identifying patients at risk
for HBOC, while 40 percent reported no confidence at all, and 20% reported being somewhat
confident. On average, 80% of providers reported 0-3 patients per month that they identified atrisk patients for HBOC and refer to genetics for counseling. While 20% reported 5-10 patients
per month identified and referred to genetics for counseling 100% of providers participating in
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these surveys reported not using a screening tool to assess patients at an increased risk for
HBOC.
The pre-implementation knowledge questions showed that all providers scored an
average of 65% on the clinical situational knowledge questions. Providers with 3-9 years of
experience who felt very confident in identifying patients at risk for HBOC scored an average of
100% on the clinical scenario knowledge questions. Providers with 10+ years of experience who
felt very confident in identifying patients at risk for HBOC scored an average of 50 % on the
clinical scenario knowledge questions. Providers with 10 + years of experience who felt
somewhat confident in identifying patients at risk for HBOC scored an average of 100% on the
clinical scenario knowledge questions and providers with 10+ years of experience who felt not at
all confident in identifying patients at risk for HBOC scored an average of 37.5%. As this cohort
of participants is small, it does not reflect the national average PCP knowledge nor does this
quality improvement project reflect the standard or average knowledge of PCPs at the University
of Miami. Though these results do reflect what has been noted in the literature. As predicted, the
PCPs involved in this project have a variable range of knowledge of HBOC. The findings
suggest that clinical knowledge is independent of experience or confidence. Providers with 3-9
years of experience who felt very confident in identifying patients at risk for HBOC scored an
average of 100% on the clinical scenario knowledge questions, Whereas Providers with 10+
years of experience who felt very confident in identifying patients at risk for HBOC scored an
average 50 % on the clinical scenario knowledge questions.
Post implementation, survey results showed that 100% of participants found the family
history screening tool helpful in identifying patients at an increased risk for HBOC. An average
of 66.7% of participants rated and felt as very confident in identifying patients at an increased
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risk for HBOC while using the family history screening tool while 33.3% rated and felt as
somewhat confident. In comparing the pre-implementation results to at-risk patient scenarios
where no family history screening tool was utilized versus post-implementation results where a
family history screening tool was utilized, we can see that on average, participants' average
scores were better when utilizing the family history screening tool.
Question 1 assessed Providers' knowledge of inheritance patterns, in both pre- and postsurveys participants, who scored this answered correctly 100% of the time. Question 2 assessed
the identification that any patient with a family history of a woman with a breast cancer
diagnosis before the age of 50 should initiate a referral for genetic counseling, preimplementation of the family history screening tool provider's average score was 60% while the
implementation of the tool revealed a 66.7% rate of identifying at-risk patients. Question 3
assessed the identification that a patient with a family history of 2 or more relatives with a
diagnosis of breast cancer should initiate a referral for genetic counseling, pre-implementation of
the tool, providers' average score was 80% while post-implementation with the tool was 66.7%.
Question 4 assessed the identification that any first-degree relative with a history of breast cancer
should initiate a referral for genetic counseling. Pre-implementation of the tool, the average score
was 40% while post-implementation was 100%. Question 5 assessed the identification that any
relative with a diagnosis of bilateral breast cancer should initiate a referral for genetic
counseling, pre-implantation of the tool result was 80% while post-implementation was 100%.
As previously mentioned, this cohort of participants is small, and it does not reflect the
national average PCP knowledge, nor does this reflect the standard or average knowledge of
PCPs at this institution. Though these results do reflect what has been noted in the literature. As
predicted, PCPs have a variable range of knowledge of HBOC. For example, one study revealed
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that among primary care providers, there were several gaps identified in BRCA1/2 knowledge
(Dekanek et al., 2019). The average score to correct answers to knowledge questions for
BRCA1/2 was 73%. As demonstrated previously, the average correct answer to knowledge
questions amongst all providers in the pre-implementation survey was 65%. As identified, there
is a variable range of knowledge when it comes to HBOC. These findings also suggest clinical
knowledge is independent of experience or confidence. Providers with 3-9 years of experience
who felt very confident in identifying patients at risk for HBOC scored an average of 100% on
the clinical scenario knowledge questions. Whereas providers with 10+ years’ experience who
felt very confident in identifying patients at risk for HBOC scored an average of 50 % on the
clinical scenario knowledge questions pre-implementation of the family history screening tool.
Post-implementation of the family history screening tool, participants rated the tool as
very helpful in identifying patients at an increased risk for HBOC. An average of 66.7% of
participants rated and felt as very confident in identifying patients at an increased risk for HBOC
while using the family history screening tool while 33.3% rated and felt as somewhat confident.
On average, the post-implementation clinical scenario questions while utilizing the family
history screening tool showed an increase in the identification of patients at risk for HBOC.

Implications To Advanced Nursing Practice
HBOC as previously mentioned is a genetic condition that is associated with the genes
BRCA 1 and BRCA2. Having a pathogenic variant in one of these genes increases an
individual’s lifetime risk of developing certain cancers such as breast, ovarian, pancreatic,
prostate, and melanoma, greater than the average person’s risk (Owens et al., 2019). As genetics
is an ever-evolving field with fast-changing and continued advancements in technology, it may
not be clear to primary care providers who should be evaluated by a genetics specialist. As noted
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in the literature, there was a knowledge gap noted in the primary care setting of what patients are
at an increased risk for HBOC. As seen in this quality improvement project, results also mirrored
what is seen in the literature, a knowledge gap in the primary care setting as it relates to the
identification of patients at risk for HBOC. The goal and implications to the advanced nursing
practice of this quality improvement project were to identify this knowledge gap and increase the
awareness and knowledge of primary care providers of the available family history screening
tools and guidelines that are in place for HBOC.
Primary care providers are the gatekeepers to patients’ health and the frontline to patients'
health maintenance and screening. Increasing awareness, knowledge, and resources for primary
care providers about HBOC can aid in increasing the identification of this patient population and
these patients at risk can receive the increased screening that is recommended for them in order
to reduce their risk of developing cancer.
Screening tools help to identify patients at risk and help providers to refer patients to
treatment and or avoid and reduce symptoms, thus improving healthcare outcomes for patients
while decreasing healthcare costs and burdens (Iragorri & Spackman, 2018). The information
and data gathered from this project can lead to the incorporation of a clinical decision support
tool in the electronic health record. Clinical decision support tools can be a promising approach
to identifying patients who are at an increased risk for hereditary cancers (Del Fiol et al., 2020).
One study conducted by authors Del Fiol et al. (2020), concluded that implementing clinical
decision support tools to identify patients at an increased risk for hereditary cancers had several
strengths, one of which included building on PCP workflow without creating an additional
burden. The authors Del Fiol et al. (2020), also concluded that patients at risk for hereditary
cancers were successfully identified using a criteria-based clinical decision platform.
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On further validation of my theory that there is a knowledge gap with regard to HBOC in
the primary care setting and that the use of family history screening tools can aid in the increase
of identification of this patient population, this project can be expanded to include clinical
decision-making tools in the electronic health record. Evidence from scholarly studies should
drive clinical practice, and the way that cares is delivered to patients. Translating research
evidence into clinical practice is key to efficient healthcare delivery and serving the community
to provide effective and efficient care (Curtis et al., 2017).

Conclusion
Genetics is an ever-evolving field, and as a discipline, there have been advances and
changes in the guidelines that are used in identifying patients at risk for HBOC. There are now
recommended guidelines and tools that can be used in the primary care setting to assist primary
care providers in the identification of patients at risk for HBOC. This quality improvement
project aimed to identify if there was a knowledge gap in the primary care setting in regard to
PCP knowledge and HBOC. While also providing PCPs with the resources and tools needed to
improve their knowledge and identify patients at risk for HBOC. A paired sample T-test was
performed on the data collected from the project’s pre-implementation and post-implementation
surveys and it revealed that there was no statistical significance. There were challenges in the
project timeline in recruiting and maintaining the engagement of the participants, which led to a
small sample size. Although this was a small group and non-statistically significant in the
conclusions of this project, this quality improvement project reflected what is seen from PCP
knowledge variability in the HBOC literature.
Descriptive statistics did reveal that using a screening tool can potentially improve the
identification of patients at risk for HBOC. As average scores of participants ability to identify at
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risk patient’s pre-implementation and post-implementation of a family history screening tool
improved. Further validation of the theory that there is a knowledge gap of HBOC in the PCP
setting and that a family history screening tool can aid in the increase of identification of this
patient population will need to be explored further for more statistical significance and approach.
In closing, further validation is needed but ultimately educating providers and identifying
patients at risk for HBOC can increase patient opportunity for risk-reducing screening and
procedures and thus potentially improve patient health care outcomes. Further expansion of this
project to include clinical decision-making tools can potentially aid in further validating this
theory and translating research into changing practice.
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Appendices
Appendix A
A. Project Timeline
February 1, 2022

• Description of research problem and project purpose

February 20, 2022

• Completion of literature review

March 15, 2022

• Project planning, assessment of feasibility, and SWOT
analysis

April 17, 2022

• Project proposal

May 2, 2022

• Project proposal to UM IRB

June 6, 2022

• Recruitment of PCPs for quality improvement project

June 27, 2022

• Send initial survey and educational materials to
participants to incorporate into practice
• PCPs to incorporate family history screening tools into
their practice

July-August 2022

• Send final questionnaire to participating PCPs

September 30, 2022

• Data and survey collection

October 30, 2022

• Data compliation, statistical anylysis and finalzation of
the project

November 10, 2022

Updated Plan/Project Milestones
Milestones

Description

Estimated Completion date
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REDcap web platform

Begin the making of REDcap

July 20, 2022 *REDcap

platform which includes

platform cannot be made until

making potential participant

there is IRB approval.

list and surveys for
distribution

Potential Participants

Send out emails to potential

July 22, 2022

participants to participate in

July 29 (Reminder)

QI project (Within this email
it will lead potential
participants to the consent
and once consented they will
be lead to the survey).
Potential participants will be
given two weeks to respond
to survey. A reminder will be
sent out after one week.

Distribution of Family history Once survey is complete,
screening tool

educational materials/family
history screening tool will be
distributed to participants to
begin use in their practice.

August 5, 2022
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Implementation of tool

Participants will be given 8

October 3, 2022

weeks to implement
educational materials/ family
history screening tool.

Post Implementation Survey

Send out post implementation

October 4, 2022

surveys to participants.

October 11 (Reminder)

Participants will be given two
week to respond to survey. A
follow up reminder will be
sent after one week.

Data analysis

By end-October begin
analyzing data and conclude
findings of QI project in
November.

(Moran et al., 2020)

October 31, 2022
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Appendix B
B. Evidence-based Practice Guidelines Supporting Genetic Susceptibility Testing for
Hereditary Breast and Ovarian Cancer Syndrome
United States Preventive Services Task Force (USPSTF) Recommendations (2019)1
The USPSTF recommends that “primary care clinicians assess women with a personal or family
history of breast, ovarian, tubal, or peritoneal cancer or who have an ancestry associated with
BRCA1/2 gene mutations with an
appropriate brief familial risk assessment tool.”


Family history screening tools include
o Ontario Family History Assessment Tool
o Manchester Scoring System
o Referral Screening Tool
o Pedigree Assessment Tool
o 7-Question Family History Screening Tool
o International Breast Cancer Intervention Study instrument (Tyrer-Cuzick)
o Brief versions of BRCAPRO



“Women with a positive result on the risk assessment tool should receive genetic
counseling and, if indicated after counseling, genetic testing.”



The USPSTF recommendation includes the following personal or family health histories
as examples of increased likelihood of having a BRCA mutation:
o Breast cancer diagnosed before age 50
o Bilateral breast cancer
o Presence of both breast and ovarian cancer in the same person
o Breast cancer in a male
o Multiple cases of breast cancer in the family
o One or more family members with two primary types of BRCA-related cancer
o Ashkenazi (Eastern European) Jewish ancestry
o Family member with a known harmful genetic mutation in the BRCA1 or BRCA2
gene

Other recommendations


National Comprehensive Cancer Network (NCCN) (2019) Recommendations3
o Referral for BRCA genetic counseling is recommended for individuals with a
personal history of any of the following or a first- or second-degree relative
(mother, father, brother, sister, child, grandparent, aunt, uncle, niece, or nephew)
with any of the following:
 Family member with a known pathogenic or likely pathogenic BRCA
mutation
 Ovarian carcinoma
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Male breast cancer
Pancreatic cancer
Metastatic prostate cancer
Female breast cancer and one or more of the following
 Diagnosed ≤ age 45
 Diagnosed age 46-50 with:
o Another breast cancer primary at any age
o ≥ 1 close blood relative with breast cancer or high grade
(Gleason score ≥7) prostate cancer at any age
o An unknown or limited family history
 Diagnosed ≤ age 60 with triple negative breast cancer
 Diagnosed at any age with
o ≥ 1 close blood relative with
 breast cancer diagnosed ≤ age 50
 ovarian carcinoma
 male breast cancer
 metastatic prostate cancer
 pancreatic cancer
o ≥ 2 close blood relatives with breast cancer at any age
o ≥ 2 additional breast cancer primaries at any age
o Ashkenazi or Eastern European Jewish ancestry
High grade prostate cancer (Gleason score ≥7) at any age and one or more
of the following
 ≥ 1 close blood relatives with
o Ovarian carcinoma at any age
o Pancreatic cancer at any age
o Metastatic prostate cancer at any age
o Breast cancer ≤50 years
 ≥ 2 close blood relatives with
o Breast cancer at any age
o Prostate cancer (any grade) at any age
 Ashkenazi (Eastern European) Jewish ancestry
BRCA1/2 pathogenic or likely pathogenic mutation detected by tumor
profiling in the absence of germline mutation analysis

American College of Medical Genetics (ACMG) and National Society of Genetic
Counselors (NSGC) Recommendations (2014)4
o Referral for genetic counseling for BRCA is recommended for individuals with a
personal or family heath history of
 Breast cancer diagnosed ≤ age 50
 Triple-negative breast cancer diagnosed ≤ age 60
 Two or more primary breast cancers
 Ovarian, fallopian tube, or primary peritoneal cancer
 Male breast cancer
 Ashkenazi Jewish or Eastern European ancestry and breast or pancreatic
cancer at any age
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•

Breast, ovarian, or pancreatic cancer and two or more cases of breast,
ovarian, pancreatic, or aggressive prostate cancer in close blood relatives
Aggressive prostate cancer and two or more cases of breast, ovarian, or
pancreatic cancer in close blood relatives
Aggressive prostate cancer and two or more cases of breast, ovarian, or
pancreatic cancer in close blood relatives

(Centers for Disease Control and Prevention, 2021b)
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